Medigene Obtains U.S. Patent for EndoTAG®-1 for the Treatment of Triple-Negative Breast Cancer
(Thomson Reuters ONE) -
MediGene AG /
Medigene Obtains U.S. Patent for EndoTAG®-1 for the Treatment of Triple-Negative
Breast Cancer
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, May 2, 2012. MediGene AG (Frankfurt, Prime Standard) has
obtained an additional patent for oncology drug candidate, EndoTAG(®)-1, from
the United States Patent and Trademark Office. Patent No. 8,168,216 protects the
use of EndoTAG(®)-1 in combination with taxanes for the treatment of triple-
negative breast cancer (TNBC). This drug combination was successfully tested in
a phase II clinical trial in patients with TNBC. This newly granted patent
broadens the existing EndoTAG(®)-1 patent portfolio and has a regular term until
April 2029.
About EndoTAG(®)-1: EndoTAG(®)-1 is a novel composition of the established
cytostatic drug paclitaxel combined with neutral and positive lipids. The
positively charged lipids imply that EndoTAG(®)-1 interacts with newly
developed, negatively charged endothelial cells, which are primarily required
for the growth of tumor blood vessels. The EndoTAG(®)-1 paclitaxel component
attacks the endothelial cells as they divide, thus targeting the blood supply to
tumors without affecting the supply to healthy tissue. By doing this,
EndoTAG(®)-1 is expected to prevent the formation of new tumor blood vessels and
to inhibit tumor growth.
Medigene has successfully completed two clinical phase II trials of EndoTAG(®)-
1 in the indications pancreatic cancer and triple-negative breast cancer (TNBC).
EndoTAG(®)-1 has been designated orphan drug status in Europe and the USA for
the treatment of pancreatic cancer. This designation has advantages for the
development, approval and, under certain circumstances, the marketing of drugs.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and EndoTAG(®) are registered trademarks of MediGene AG. These
trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology.
Contact
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as pdf:
http://hugin.info/132073/R/1607406/509874.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1607406]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2012 - 01:30 Uhr
Sprache: Deutsch
News-ID 1109413
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 67 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene Obtains U.S. Patent for EndoTAG®-1 for the Treatment of Triple-Negative Breast Cancer
"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
